Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Liabilities and Shareholders Equity: 2009-2024

Historic Liabilities and Shareholders Equity for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $1.4 billion.

  • Cytokinetics' Liabilities and Shareholders Equity rose 0.03% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 16.02%. This contributed to the annual value of $1.4 billion for FY2024, which is 70.04% up from last year.
  • As of FY2024, Cytokinetics' Liabilities and Shareholders Equity stood at $1.4 billion, which was up 70.04% from $824.3 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Liabilities and Shareholders Equity registered a high of $1.4 billion during FY2024, and its lowest value of $533.8 million during FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.1 billion, with a median of $1.0 billion in 2022.
  • In the last 5 years, Cytokinetics' Liabilities and Shareholders Equity spiked by 84.19% in 2020 and then fell by 18.77% in 2023.
  • Over the past 5 years, Cytokinetics' Liabilities and Shareholders Equity (Yearly) stood at $533.8 million in 2020, then skyrocketed by 57.61% to $841.3 million in 2021, then climbed by 20.62% to $1.0 billion in 2022, then decreased by 18.77% to $824.3 million in 2023, then surged by 70.04% to $1.4 billion in 2024.